Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsayil LTE long-term extension study of spesolimab in hidradenitis suppurativa
MOH_2024-05-29_013434Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started May 2024; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2024-05-29_013434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-29_013434.